In HCC, the anti-PD-1 antibodies and the anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antibodies have been approved for second-line treatment (Pinter et al., 2021). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.